Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin Interruption vs Continuation in Soft Tissue Sarcoma
NCT03773510Phase 3Withdrawn
- Sponsor
- Italian Sarcoma Group
- Start
- Feb 2019
- Primary completion
- Oct 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trabectedin in leiomyosarcoma (LMS), Liposarcoma and synovial sarcoma (SS) (2 arms), sponsored by Italian Sarcoma Group. Primary endpoint: Time to secondary resistance to Trabectedin at Week 18. Planned start Feb 2019; status: withdrawn.
02
Drugs
trabectedin
03
Conditions
leiomyosarcoma (LMS)Liposarcomasynovial sarcoma (SS)
Beyond the preview
Go deeper on NCT03773510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773510.